<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02476279</url>
  </required_header>
  <id_info>
    <org_study_id>U01DK104833-01</org_study_id>
    <secondary_id>U01DK104833-01</secondary_id>
    <nct_id>NCT02476279</nct_id>
  </id_info>
  <brief_title>Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis</brief_title>
  <acronym>SVI</acronym>
  <official_title>Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis: The SVI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Pancreatitis is the most frequent complication of endoscopic retrograde&#xD;
      cholangiopancreatography (ERCP), accounting for substantial morbidity, occasional mortality,&#xD;
      and increased health care expenditures. Until recently, the only effective method of&#xD;
      preventing post-ERCP pancreatitis (PEP) had been prophylactic pancreatic stent placement&#xD;
      (PSP), an intervention that is costly, time consuming, technically challenging, and&#xD;
      potentially dangerous. The investigators recently reported the results of a large randomized&#xD;
      controlled trial demonstrating that rectal indomethacin, a non-steroidal anti-inflammatory&#xD;
      drug, reduced the risk of pancreatitis after ERCP in high-risk patients, most of whom (&gt;80%)&#xD;
      had received a pancreatic stent. Secondary analysis of this RCT suggested that subjects who&#xD;
      received indomethacin alone were less likely to develop PEP than those who received a&#xD;
      pancreatic stent alone or the combination of indomethacin and stent, even after adjusting for&#xD;
      underlying differences in subject risk. If indomethacin were to obviate the need for PSP,&#xD;
      major clinical and cost benefits in ERCP practice could be realized.&#xD;
&#xD;
      Objective: To assess whether rectal indomethacin alone is non-inferior to the combination of&#xD;
      rectal indomethacin and prophylactic pancreatic stent placement for preventing post-ERCP&#xD;
      pancreatitis in high-risk cases.&#xD;
&#xD;
      Methods: Comparative effectiveness multi-center non-inferiority trial of rectal indomethacin&#xD;
      alone vs. the combination of rectal indomethacin and prophylactic pancreatic stent placement&#xD;
      for the prevention of post-ERCP pancreatitis in high-risk patients. One thousand four hundred&#xD;
      and thirty subjects at elevated risk for PEP who would normally receive a pancreatic stent&#xD;
      for prophylaxis will be randomized to indomethacin alone or the combination of indomethacin&#xD;
      and PSP. The proportion of patients developing PEP and moderate-severe PEP will be compared.&#xD;
      In addition, the investigators will establish a quality-assured central repository of&#xD;
      biological specimens obtained from study participants, permitting future translational&#xD;
      research elucidating the molecular and genetic mechanisms of PEP, as well as the mechanisms&#xD;
      by which non-steroidal anti-inflammatory drugs prevent this complication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects in each study group with post-ERCP pancreatitis</measure>
    <time_frame>Within 48 hours after ERCP</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects in each study group with moderate-severe post-ERCP pancreatitis</measure>
    <time_frame>Within one month of ERCP</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2180</enrollment>
  <condition>Post-ERCP Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Indomethacin alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indomethacin 100 mg rectally immediately after ERCP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indomethacin+pancreatic stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement</intervention_name>
    <arm_group_label>Indomethacin alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement</intervention_name>
    <arm_group_label>Indomethacin+pancreatic stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Any patient undergoing ERCP in whom pancreatic stent placement is planned for post-ERCP&#xD;
        pancreatitis prevention, is ≥ 18 years old, who provides informed consent, AND:&#xD;
&#xD;
        Has one of the following:&#xD;
&#xD;
          1. Clinical suspicion of or known sphincter of Oddi dysfunction&#xD;
&#xD;
          2. History of post-ERCP pancreatitis (at least one prior episode of pancreatitis after&#xD;
             ERCP)&#xD;
&#xD;
          3. Pancreatic sphincterotomy&#xD;
&#xD;
          4. Pre-cut (access) sphincterotomy (freehand pre-cut and septotomy)&#xD;
&#xD;
          5. Difficult cannulation: cannulation duration ≥ 6 minutes (starting at time of initial&#xD;
             papillary engagement with at least 25% of the time in contact with the papilla) AND/OR&#xD;
             ≥ 6 cannulation attempts (defined as sustained contact with papilla lasting at least 1&#xD;
             second).&#xD;
&#xD;
          6. Short-duration (≤ 1 min) balloon dilation of an intact biliary sphincter.&#xD;
&#xD;
             Or has at least 2 of the following:&#xD;
&#xD;
          7. Age &lt; 50 years old &amp; female gender&#xD;
&#xD;
          8. History of recurrent pancreatitis (at least 2 episodes)&#xD;
&#xD;
          9. ≥3 pancreatic injections&#xD;
&#xD;
         10. Pancreatic acinarization&#xD;
&#xD;
         11. Pancreatic brush cytology&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ampullectomy&#xD;
&#xD;
          2. Cases in which a pancreatic stent must be placed for therapeutic intent&#xD;
&#xD;
          3. Unwillingness or inability to consent for the study&#xD;
&#xD;
          4. Pregnancy&#xD;
&#xD;
          5. Breast feeding mother&#xD;
&#xD;
          6. Standard contraindications to ERCP&#xD;
&#xD;
          7. Allergy to Aspirin or NSAIDs&#xD;
&#xD;
          8. Known renal failure (Cr &gt; 1.4 mg/dl)&#xD;
&#xD;
          9. Ongoing or recent (within 2 weeks) hospitalization for gastrointestinal hemorrhage&#xD;
&#xD;
         10. Ongoing or recent (within 1 week) hospitalization for acute pancreatitis&#xD;
&#xD;
         11. Known chronic calcific pancreatitis&#xD;
&#xD;
         12. Pancreatic head malignancy&#xD;
&#xD;
         13. Procedure performed on major papilla/ventral pancreatic duct in patient with pancreas&#xD;
             divisum (no manipulation of minor papilla)&#xD;
&#xD;
         14. ERCP for biliary stent removal or exchange without anticipated pancreatogram&#xD;
&#xD;
         15. Subjects with prior biliary sphincterotomy now scheduled for repeat biliary therapy&#xD;
             without anticipated pancreatogram&#xD;
&#xD;
         16. Anticipated inability to follow protocol&#xD;
&#xD;
         17. Absence of rectum&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>B. Joseph Elmunzer, MD</last_name>
    <email>elmunzer@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca Spitzer, MPH</last_name>
    <phone>843-876-4303</phone>
    <email>spitzer@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Univesrity of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Buxbaum</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sachin Wani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Field Willingham</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajesh Keswani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikesh Singh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Schieman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Edmundowicz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth University</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Gardner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amitabh Chak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgios Papachristou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Elmunzer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Yachimski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Ross</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2015</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Badih Elmunzer</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

